Literature DB >> 19179483

Down-regulation of hepatic HNF4alpha gene expression during hyperinsulinemia via SREBPs.

Xuefen Xie1, Hailing Liao, Huaixin Dang, Wei Pang, Youfei Guan, Xian Wang, John Y-J Shyy, Yi Zhu, Frances M Sladek.   

Abstract

Mutations in the coding region of hepatocyte nuclear factor 4alpha (HNF4alpha), and its upstream promoter (P2) that drives expression in the pancreas, are known to lead to maturity-onset diabetes of the young 1 (MODY1). HNF4alpha also controls gluconeogenesis and lipid metabolism in the liver, where the proximal promoter (P1) predominates. However, very little is known about the role of hepatic HNF4alpha in diabetes. Here, we examine the expression of hepatic HNF4alpha in two diabetic mouse models, db/db mice (type 2, insulin resistant) and streptozotocin-treated mice (type 1, insulin deficient). We found that the level of HNF4alpha protein and mRNA was decreased in the liver of db/db mice but increased in streptozotocin-treated mice. Because insulin increases the activity of sterol regulatory element-binding proteins (SREBP)-1c and -2, we also examined the effect of SREBPs on hepatic HNF4alpha gene expression and found that, like insulin, ectopic expression of SREBPs decreases the level of hepatic HNF4alpha protein and mRNA both in vitro in primary hepatocytes and in vivo in the liver of C57BL/6 mice. Finally, we use gel shift, chromatin immunoprecipitation, small interfering RNA, and reporter gene analysis to show that SREBP2 binds the human HNF4alpha P1 promoter and negatively regulates its expression. These data indicate that hyperinsulinemia down-regulates HNF4alpha in the liver through the up-regulation of SREBPs, thereby establishing a link between these two critical transcription factor pathways that regulate lipid and glucose metabolism in the liver. These findings also provide new insights into diabetes-associated complications such as fatty liver disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19179483      PMCID: PMC2667705          DOI: 10.1210/me.2007-0531

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  61 in total

Review 1.  Sterol regulatory element-binding proteins (SREBPs): transcriptional regulators of lipid synthetic genes.

Authors:  H Shimano
Journal:  Prog Lipid Res       Date:  2001-11       Impact factor: 16.195

2.  Insulin selectively increases SREBP-1c mRNA in the livers of rats with streptozotocin-induced diabetes.

Authors:  I Shimomura; Y Bashmakov; S Ikemoto; J D Horton; M S Brown; J L Goldstein
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-23       Impact factor: 11.205

3.  Adenovirus-mediated overexpression of dominant-negative mutant of c-Jun prevents intercellular adhesion molecule-1 induction by LDL: a critical role for activator protein-1 in endothelial activation.

Authors:  N Wang; L Verna; A Ballard; Y Zhu; M B Stemerman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-09       Impact factor: 8.311

4.  Dual role of transcription factor FoxO1 in controlling hepatic insulin sensitivity and lipid metabolism.

Authors:  Michihiro Matsumoto; Seongah Han; Tadahiro Kitamura; Domenico Accili
Journal:  J Clin Invest       Date:  2006-08-10       Impact factor: 14.808

5.  Sterol regulatory element-binding protein 1 is negatively modulated by PKA phosphorylation.

Authors:  Min Lu; John Y-J Shyy
Journal:  Am J Physiol Cell Physiol       Date:  2005-12-28       Impact factor: 4.249

6.  Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes.

Authors:  Jay D Horton; Nila A Shah; Janet A Warrington; Norma N Anderson; Sahng Wook Park; Michael S Brown; Joseph L Goldstein
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-25       Impact factor: 11.205

Review 7.  Modulation of sterol regulatory element binding proteins (SREBPs) as potential treatments for non-alcoholic fatty liver disease (NAFLD).

Authors:  Mohamed H Ahmed; Christopher D Byrne
Journal:  Drug Discov Today       Date:  2007-08-27       Impact factor: 7.851

8.  ATF6 modulates SREBP2-mediated lipogenesis.

Authors:  Lingfang Zeng; Min Lu; Kazutoshi Mori; Shengzhan Luo; Amy S Lee; Yi Zhu; John Y-J Shyy
Journal:  EMBO J       Date:  2004-02-05       Impact factor: 11.598

9.  SREBP-1c mediates the insulin-dependent hepatic glucokinase expression.

Authors:  So-Youn Kim; Ha-il Kim; Tae-Hyun Kim; Seung-Soon Im; Sang-Kyu Park; In-Kyu Lee; Kyung-Sup Kim; Yong-Ho Ahn
Journal:  J Biol Chem       Date:  2004-04-30       Impact factor: 5.157

Review 10.  Insulin regulation of phosphoenolpyruvate carboxykinase-c gene transcription: the role of sterol regulatory element-binding protein 1c.

Authors:  Kaushik Chakravarty; Richard W Hanson
Journal:  Nutr Rev       Date:  2007-06       Impact factor: 7.110

View more
  40 in total

1.  Modification in oxidative stress, inflammation, and lipoprotein assembly in response to hepatocyte nuclear factor 4alpha knockdown in intestinal epithelial cells.

Authors:  Valérie Marcil; Ernest Seidman; Daniel Sinnett; François Boudreau; Fernand-Pierre Gendron; Jean-François Beaulieu; Daniel Ménard; Louis-Philippe Precourt; Devendra Amre; Emile Levy
Journal:  J Biol Chem       Date:  2010-09-24       Impact factor: 5.157

2.  Perilipin-5 is regulated by statins and controls triglyceride contents in the hepatocyte.

Authors:  Cédric Langhi; Tyler J Marquart; Ryan M Allen; Angel Baldán
Journal:  J Hepatol       Date:  2014-04-21       Impact factor: 25.083

3.  The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial.

Authors:  Yumie Takeshita; Toshinari Takamura; Masao Honda; Yuki Kita; Yoh Zen; Ken-ichiro Kato; Hirofumi Misu; Tsuguhito Ota; Mikiko Nakamura; Kazutoshi Yamada; Hajime Sunagozaka; Kuniaki Arai; Tatsuya Yamashita; Eishiro Mizukoshi; Shuichi Kaneko
Journal:  Diabetologia       Date:  2014-01-10       Impact factor: 10.122

Review 4.  Dyslipidaemia of diabetes and the intestine.

Authors:  Gerald H Tomkin; Daphne Owens
Journal:  World J Diabetes       Date:  2015-07-10

5.  Ezetimibe in the balance: can cholesterol-lowering drugs alone be an effective therapy for NAFLD?

Authors:  Giovanni Musso
Journal:  Diabetologia       Date:  2014-02-20       Impact factor: 10.122

6.  Impairment of hepatic nuclear factor-4α binding to the Stim1 promoter contributes to high glucose-induced upregulation of STIM1 expression in glomerular mesangial cells.

Authors:  Yanxia Wang; Sarika Chaudhari; Yuezhong Ren; Rong Ma
Journal:  Am J Physiol Renal Physiol       Date:  2015-03-18

7.  MicroRNAs regulate human hepatocyte nuclear factor 4alpha, modulating the expression of metabolic enzymes and cell cycle.

Authors:  Shingo Takagi; Miki Nakajima; Katsuhiko Kida; Yu Yamaura; Tatsuki Fukami; Tsuyoshi Yokoi
Journal:  J Biol Chem       Date:  2009-12-15       Impact factor: 5.157

Review 8.  Cooperative and individualistic functions of the microRNAs in the miR-23a~27a~24-2 cluster and its implication in human diseases.

Authors:  Ravindresh Chhabra; Richa Dubey; Neeru Saini
Journal:  Mol Cancer       Date:  2010-09-03       Impact factor: 27.401

9.  Hepatocyte nuclear factor 4alpha coordinates a transcription factor network regulating hepatic fatty acid metabolism.

Authors:  Celia Pilar Martinez-Jimenez; Irene Kyrmizi; Philippe Cardot; Frank J Gonzalez; Iannis Talianidis
Journal:  Mol Cell Biol       Date:  2009-11-23       Impact factor: 4.272

10.  Role for sterol regulatory element binding protein-1c activation in mediating skeletal muscle insulin resistance via repression of rat insulin receptor substrate-1 transcription.

Authors:  Yan Bi; Wenjun Wu; Junfeng Shi; Hua Liang; Wenwen Yin; Yingying Chen; Sunyinyan Tang; Shu Cao; Mengyin Cai; Shanmei Shen; Qian Gao; Jianping Weng; Dalong Zhu
Journal:  Diabetologia       Date:  2013-12-21       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.